Hester Biosciences reports 16% yoy growth in sales; Stock surges ~3%

31 Jan 2022 , 03:03 PM

Hester Biosciences Ltd. has announced its results for the quarter ended December 2021, following this its scrip was seen up by 3.44% or Rs 82.40 to trade at Rs 2,478.35 against its previous closing price of Rs 2,395.95. So far it has touched an intraday high and low of Rs 2,524.95 and Rs 2,242.35 respectively.

The company reported net revenue of Rs 54 crores for Q3FY22 against Rs 52.82 crore for Q3 FY’21, reflecting a growth of 2% YoY. While its revenue for the 9M period ending December 2021 stood at Rs 169.10 crore as against a revenue of Rs 145.30 crores for the previous 9M period, registering a growth of 16% YoY.

The company’s profit narrowed by 21% to Rs 10.56 crore for the quarter ended December 2021, against Rs 13.30 crore for the previous corresponding quarter. While profit for the overall 9M period ending December 2021 has registered a growth of 11% at 34.60 crores against Rs 31 crore for the previous 9M period.

Its EBITDA margin stood at 28.21% for Q3 FY’22 against 38.97% for Q3 FY’21.

The company’s domestic sales expanded near 3% in Q3 FY’22, and 24% in Q3 FY’21. While its exports have improved drastically by 88% in Q3 FY’22 whilst it grew by 14% for the complete quarter.